Cover Image
Read Now

CADTH Canadian Drug Expert Committee final recommendation: Emtricitabine / tenofovir alafenamide (Descovy -- Gilead Sciences Canada, Inc.) indication : HIV-1 infection

The CADTH Canadian Drug Expert Committee (CDEC) recommends that emtricitabine/tenofovir alafenamide (FTC/TAF) be reimbursed for use in combination with other antiretrovirals (ARVs) (such as non-nucleoside reverse transcriptase inhibitors [NNRTIs] or protease inhibitors) for the treatment of human im...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2016, August 24, 2016
Series:Common drug review
Subjects:
Insurance, Health, Reimbursement
Drug Combinations
Canada
Tenofovir / Therapeutic Use
Emtricitabine / Therapeutic Use
Emtricitabine / Economics
Tenofovir / Economics
Hiv Infections / Drug Therapy
Drug Costs
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that emtricitabine/tenofovir alafenamide (FTC/TAF) be reimbursed for use in combination with other antiretrovirals (ARVs) (such as non-nucleoside reverse transcriptase inhibitors [NNRTIs] or protease inhibitors) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients aged 12 years and older
Physical Description:1 PDF file (5 pages)

Similar Items